GW Pharmaceuticals, the biopharmaceutical company focused on developing cannabis-based therapeutics, has announced that Sativex, its treatment for spasticity in Multiple Sclerosis, has been determined by Advisory Council on Misuse of Drugs (ACMD) that has a low potential for abuse and low risk of diversion.
Sativex can now be prescribed in the UK with no restriction on supply, recording, storage or destruction. The product was recently rescheduled in the UK from Schedule 1 under the Misuse of Drugs Act to Schedule 4. The change confirms the distinction between Sativex – with its evidence of quality, safety and efficacy as recognised by…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
